本文選題：甘精胰島素　切入點：預(yù)混胰島素　出處：《中國藥房》2016年03期 　論文類型：期刊論文

【摘要】：目的:系統(tǒng)評價甘精胰島素對比預(yù)混胰島素治療2型糖尿病的療效與安全性,以為臨床提供循證參考。方法:計算機檢索Pub Med、相關(guān)期刊論文、萬方數(shù)據(jù)庫和中文科技期刊數(shù)據(jù)庫,收集甘精胰島素(試驗組)對比預(yù)混胰島素(對照組)治療2型糖尿病療效與安全性的隨機對照試驗(RCT),對符合納入標準的臨床研究進行資料提取,并采用改良后的Jadad量表進行質(zhì)量評價,采用Rev Man 5.0統(tǒng)計軟件進行Meta分析。結(jié)果:共納入10項RCT,合計1 655例患者。Meta分析結(jié)果顯示,甘精胰島素在降低糖化血紅蛋白水平[MD=-0.41,95%CI(-0.64,-0.18),P0.001]、空腹血糖水平[MD=-0.51,95%CI(-0.99,-0.02),P=0.04]方面均優(yōu)于預(yù)混胰島素,兩組比較差異均有統(tǒng)計學(xué)意義,而在降低餐后2 h血糖水平[MD=-0.56,95%CI(-1.21,0.09),P=0.09]、體質(zhì)量指數(shù)[MD=-0.52,95%CI(-1.52,0.48),P=0.31]方面,差異均無統(tǒng)計學(xué)意義;甘精胰島素組患者的低血糖發(fā)生率[RR=0.65,95%CI(0.46,0.90),P=0.01]低于預(yù)混胰島素組,差異有統(tǒng)計學(xué)意義。結(jié)論:甘精胰島素治療2型糖尿病的療效與安全性優(yōu)于預(yù)混胰島素。
[Abstract]:Objective: to evaluate the efficacy and safety of insulin glargine contrast premixed insulin in the treatment of type 2 diabetes mellitus. Wanfang Database and Chinese Sci-tech Journals Database, A randomized controlled trial of insulin glargine (trial group) compared with premixed insulin (control group) in the treatment of type 2 diabetes mellitus was conducted. The modified Jadad scale was used to evaluate the quality and the Meta analysis was carried out by Rev Man 5.0. Results: ten items were included in the total of 1 655 patients. Insulin glargine was better than premixed insulin in reducing glycosylated hemoglobin level [MD-0.41-95CI-0.64U -0.18P0.001], fasting blood glucose level [MD-0.51c95CI-0.99C -0.02U P0.04]. The difference between the two groups was statistically significant, but in reducing blood glucose level at 2 h after meal [MD-0.5695CI-1.210.09], body mass index (MD-0.52CI-95CI-1.520.48P0.31), the difference between the two groups was statistically significant, and there was no significant difference between the two groups in reducing blood glucose level at 2 h after meal (MD-0.5695CI-1.21 0.09), body mass index (MD-0.52J / 95CI-1.50.48 / P0. 31). The incidence of hypoglycemia in insulin glargine group [RRX 0.65N 95] was significantly lower than that in premixed insulin group (P 0.01). Conclusion: the efficacy and safety of insulin glargine in the treatment of type 2 diabetes mellitus is better than that in premixed insulin group.
【作者單位】： 解放軍第175醫(yī)院/廈門大學(xué)附屬東南醫(yī)院;福建中醫(yī)藥大學(xué)藥學(xué)院;
【分類號】：R587.1

【相似文獻】

相關(guān)期刊論文 前10條

1 韓相范;;淺談門診使用預(yù)混胰島素應(yīng)注意的幾個問題[J];實用糖尿病雜志;2010年03期

2 虞金嵐;;淺探預(yù)混胰島素治療2型糖尿病的臨床觀察[J];醫(yī)學(xué)信息(中旬刊);2010年07期

3 王平;李世云;;預(yù)混胰島素劑型和劑量量化選擇探討[J];四川醫(yī)學(xué);2011年07期

4 王滌非;單忠艷;;預(yù)混胰島素在特殊人群中的應(yīng)用案例分析[J];藥品評價;2012年31期

5 馮美俊;于s，

本文編號：1621010